[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530206":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":31,"locations":41,"responsibleParty":64,"collaborators":10,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":10,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Hunan Province Tumor Hospital","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"ICIs",null,"Patients receiving in first-line immunotherapy with or without anti-angiogenic or chemotherapy",[13],"Other: No treatment is included in this protocol.",{"label":15,"type":10,"description":16,"interventionNames":17},"Savolitinib","Patients receiving in first-line savolitinib treatment",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Glumetinib","Patients receiving in first-line glumetinib treatment",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Bozitinib","Patients receiving in first-line bozitinib treatment",[13],[27],{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"No treatment is included in this protocol.","No drug intervention or tissue sampling will be included in this study.",[23,19,9,15],[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Yongchang Zhang, MD","CONTACT","+8613873123436","7+861383123436","zhangyongchang@csu.edu.cn",{"name":39,"role":34,"phone":35,"phoneExt":10,"email":40},"Nong Yang","yangnong0217@163.com",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Changsha","Hunan","China","CN",{"type":49,"coordinates":50},"Point",[51,52],112.97087,28.19874,{"lat":52,"lon":51},[55,58,62],{"name":56,"role":34,"phone":57,"phoneExt":10,"email":40},"Nong Yang, MD","+86 731 89762323",{"name":59,"role":34,"phone":60,"phoneExt":10,"email":61},"Ming Zhou, MD","+86 731 89762321","zhouming243@gmail.com",{"name":56,"role":63,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":63,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Yongchang Zhang","Professor, Deputy Director of Thoracic Oncology Department","100530206","a-real-world-study-of-treatment-patterns-and-effectiveness-in-met-mutation-positive-advanced-lung-cancer-100530206",false,"NCT06183762","A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer","Real-World Treatment Patterns and Effectiveness of Targeted and Systemic Therapy in Patients With Advanced Lung Cancer Carrying MET Mutation-Positive","Inclusion Criteria:\n\n1. Patients must be ≥18 years of age.\n2. Provision of fully informed consent prior to any study specific procedures.\n3. Histologically or cytologically confirmed, unresectable stage IIIB\u002FIIIC or stage IV NSCLC.\n4. Genetic variants of tumor tissue detected by NGS.\n\nExclusion Criteria:\n\nNone.","ALL","18 Years",{"count":77,"type":78},200,"ESTIMATED","OBSERVATIONAL","This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data will be collected in a forward-looking manner. This is a descriptive observational study in which data are collected in an epidemiological manner. This study is not intended to alter or interfere with the current medical practice of the enrolled patients. Data from patients on prior treatment will be collected retrospectively, and data from patients who will be treated later and included in the study will be collected in a prospective manner. The criteria for retrospective collection were consistent with those for prospective collection. Eligible patients will be enrolled after NGS analysis of tumor tissue and informed consent has been obtained. Information required for the study will be collected (every 3 months).",[82],"Advanced Lung Cancer","2024-09-17",{"date":85,"type":86},"2024-09-19","ACTUAL",{"date":88,"type":86},"2020-01-01",{"date":90,"type":78},"2025-06-30",{"name":5,"class":6},1]